Speaker: Ilona Holcomb, PhD, Director of Bioscience of ImpriMed, Inc.
Date: January 26, 2024
Description: ImpriMed provides an anticancer drug efficacy prediction service using artificial intelligence on a patient's live cancer cell data, aiming to help oncologists personalize a treatment regimen tailored to each patient's unique cancer in both human and veterinary oncology. ImpriMed's comparative oncology platform enables new precision medicine services for both human and animal cancers.
Large-Scale Validation of a Flow Cytometry Platform for Comprehensive Immunophenotyping, Cell Size Determination, and Prognostic Stratification in Canine Lymphomas
Boosting the power of AI-based treatment outcome predictions for canine lymphoma by combining tumor and germline genetic biomarkers and live-cell analytics
Dramatically increased clinical remission rates and survival times in dogs with high-grade T-cell lymphoma and relapsed B-cell lymphoma in clinical study of AI decision support
Increased survival and remission rates in prospective study of relapsed B-cell lymphoma patients treated by oncologists using ImpriMed's AI predictions
Predicting likelihood of in vivo chemotherapy response in canine lymphoma using ex vivo drug sensitivity and immunophenotyping data in a machine learning model